Macrobid (Nitrofurantoin Monohydrate)

Nitrofurantoin is converted by bacterial nitroreductases into reactive metabolites that bind to bacterial DNA and other macromolecules. This interaction damages essential cellular components, leading to bacterial death. The drug concentrates in urine, providing targeted activity against urinary pathogens.

The dosage of Macrobid is determined by the prescribing clinician based on the patient’s age, renal function, and severity of infection. The prescriber will select the appropriate strength, frequency, and duration according to current clinical guidelines.

Nitrofurantoin’s safety in pregnancy is not fully established; it is generally avoided in the third trimester due to potential fetal risks. Use during breastfeeding should be discussed with a healthcare professional, as small amounts may be excreted in breast milk.

To request Macrobid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other oral agents such as trimethoprim‑sulfamethoxazole, nitrofurantoin offers a narrow spectrum focused on common urinary pathogens and achieves high urinary concentrations. It is often preferred for uncomplicated cystitis when local resistance patterns support its use.

Store Macrobid tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture. Keep the container tightly closed and out of direct sunlight. Do not store in the bathroom or near heat sources.

Macrobid is taken orally, usually with food or milk to improve gastrointestinal tolerance. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse reactions include pulmonary toxicity (interstitial lung disease or fibrosis), severe liver injury, hemolytic anemia in patients with G6PD deficiency, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Macrobid should be avoided in patients with known hypersensitivity to nitrofurantoin or other nitrofurans, those with severe renal impairment (creatinine clearance < 30 mL/min), individuals with G6PD deficiency, and pregnant women in the third trimester. Clinicians should assess each patient’s suitability before prescribing.